Shattuck Labs STTK 深 沪
已收盘 11-06 16:00:00 美东时间
4.62
+0.130
+2.90%
华盛通- 最 高4.765
- 今 开4.49
- 成交量 114.83万股
- 最 低 4.38
- 昨 收 4.49
- 总市值 4.64亿
- 52周最高 8.33
- 市盈率 静 --
- 换手率 1.14%
- 52周最低 1.855
- 委 比 -86.34%
- 总股本 1.00亿
- 历史最高 60.516
- 量 比 1.21
- 振 幅 8.57%
- 历史最低 0.6922
- 每 手 1
- 风险率 1.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Shattuck Labs reported third-quarter 2026 financial results with $196.3 million in cash and highlighted advancements in their DR3-targeted therapies. The company initiated Phase 2b trials for SL-325 in Crohn’s disease and plans a Phase 2 trial for hidradenitis suppurativa. SL-846 showed promising preclinical data, with plans for a Phase 1 trial in 2027. Shattuck also announced upcoming presentations at industry conferences.
11-05 13:00
Shattuck Labs收跌4.32%，成交额347.63万美元
11月3日，Shattuck Labs（STTK）收跌4.32%，报5.32美元，成交额347.63万美元，市值5.34亿美元。 行情数据 • 开盘价：5.5...
11-03 07:02
Shattuck Labs收涨0.91%，成交额392.61万美元
10月27日，Shattuck Labs（STTK）收涨0.91%，报5.54美元，成交额392.61万美元，市值5.56亿美元。 行情数据 • 开盘价：5....
10-27 06:03
Shattuck Labs收跌1.99%，成交额351.08万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:06
美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
UBS Initiates Coverage On Shattuck Labs with Buy Rating, Announces Price Target of $17
UBS analyst Alice Nettleton initiates coverage on Shattuck Labs (NASDAQ:STTK) with a Buy rating and announces Price Target of $17.
10-12 21:31
美股大行评级 | 潜在涨幅405.62%！Inventiva(IVA)获Truist Securities上调目标价至18美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持Inventiva"买入"评级，目标价从13美元升至18美元；富瑞：维持Sagimet Biosciences"买入"评级，目标价从25美元升至26美元
10-05 16:26
Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Argus Research raised the price target for Accenture Plc (NYSE:ACN) from $220 to $260. Argus Research analyst ...
10-02 20:58
Needham Maintains Buy on Shattuck Labs, Raises Price Target to $19
Needham analyst Joseph Stringer maintains Shattuck Labs (NASDAQ:STTK) with a Buy and raises the price target from $17 to $19.
10-02 18:35
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
Shattuck Labs plans to initiate a Phase 2 clinical trial for SL-325 in patients with moderate to severe hidradenitis suppurativa (HS) in 2026, with data expected in the first half of 2028. This marks the second Phase 2 indication for SL-325, expanding beyond inflammatory bowel disease (IBD). The company has appointed Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development, to lead the HS program. The trial, RECEPTIVE-HS1, will ev...
10-01 11:00
